CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Financial Statements and Exhibits
ITEM 9.01
| 99.1 | Press Release dated March 29, 2019 |
CELGENE CORP /DE/ Exhibit
EX-99.1 2 tv517471_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CELGENE SETTLES U.S. REVLIMID® PATENT LITIGATION WITH ALVOGEN Alvogen licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March 2022 date Celgene previously granted to Natco Alvogen also licensed to sell generic lenalidomide in the U.S. without volume limitation beginning on January 31,…
To view the full exhibit click here
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.
